噬菌体抗体库筛选技术

噬菌体展示技术（Ｐｈａｇｅ Ｄｉｓｐｌａｙ Ｔｅｃｈｎｏｌｏｇｙ）为制备高亲和性抗体提供了有力的工具。噬菌体抗体库的筛选是其中关键的环节,为了提高筛选效率,用包被在固体表面的抗原进行筛选的传统方法不断地被改进,如宿主菌直接洗脱和双层膜筛选系统和抗抗体替代抗原筛选系统。将噬菌体感染宿主菌的过程与筛选过程相关联,产生了选择性感染筛选系统。     

噬菌体抗体技术

抗体可变区的重键基因及轻链基因与线性噬菌体的包膜蛋白蛋白基因重组后,可以在噬菌体表面表达形成具有活性的抗体片段。通过抗原的直接筛选,可以分离得到特异性强,亲和力高的抗体分子,包括人抗体。本文就噬菌体抗体文库的构建,噬菌体抗体的分离及其应用作了简要介绍。     

噬菌体抗体库筛选技术研究进展

噬菌体抗体库技术是一项新兴的基因工程抗体技术,应用这项技术获得高特异性抗体的关键之一就是筛选环节。根据抗原性质以及筛选目的的不同,筛选方法的选择也不相同,各种筛选策略的优化对中和抗体的获得有至关重要的作用。     

交替洗脱法筛选高亲和力噬菌体肽

以人胰岛素为靶蛋白从七肽展示库中筛选高亲和力噬菌体肽,在洗脱阶段采用酸性洗脱液和高浓度靶蛋白溶液进行4次交替洗脱,选择性回收高亲和力噬菌体肽。测定滴度计算回收率,ELISA法分别测定噬菌体洗脱液整体亲和力和噬菌体单克隆的结合特性并计算亲合率。洗脱步骤采用4次交替洗脱后,第二轮第4次噬菌体的回收率比第一轮增长了1800倍,高亲和力噬菌体在洗脱液中所占比例也迅速提高,第二轮第4次洗脱液中达75％,在第三轮的各次洗脱液中几乎均达100％。建立了一种快速筛选高亲和力噬菌体肽的方法,改进后的筛选方法能使高亲和力噬菌体肽的筛选工作更为简便且效果显著。     

具有高亲和力和稳定性的人源性抗PD-L1二硫键稳定Diabody的制备

目的：对天然噬菌体抗体库进行筛选并对抗体进行体外亲和力成熟,获得高亲和力人源性抗PD-L1抗体,然后对该抗体进行二硫键稳定改造,获得具有高亲和力和稳定性的人源性抗PD-L1的二硫键稳定Diabody。方法：首先以PD-L1重组蛋白为抗原在天然噬菌体Fab抗体库中筛选Fab抗体,其次分析结合能力较好的抗PD-L1的Fab抗体可变区基因中的热点,通过对轻链、重链CDR3区的7处热点随机突变构建噬菌体抗体突变库,从中筛选出亲和力得到提高的抗体。最后在抗体骨架区引入两个二硫键,构建二硫键稳定的抗PD-L1的ds-Diabody,并在毕赤酵母GS115中进行表达。结果：该方法筛选获得了6株特异性抗PD-L1噬菌体Fab抗体,对结合能力较好的其中一株抗体CDR3区的热点进行随机突变,成功构建库容为1.14×10⁸ CFU/mL的噬菌体抗体突变库,并从中筛选出亲和力提高约6倍的噬菌体抗体突变株。对该抗体骨架区进行二硫键引入,成功构建与表达二硫键稳定的ds-Diabody。结论：构建的ds-Diabody比Fab抗体与PD-L1结合亲和力高、稳定性好,为药物开发、肿瘤治疗等研究P...     

噬菌体抗体库技术的研究进展

从显示在丝状噬菌体表面的重组抗体库中选择抗体的方法已成为获得试剂、诊断及治疗的重要手段。本文介绍该技术的原理、发展及运用,但着重描述如何利用细胞筛选、改进洗脱条件、增加库容及进一步筛选以获得高亲和力抗体的方法。     

抗P-选择蛋白人源性单克隆抗体的制备

目的:获得人源性抗P-选择蛋白(selectin)特异性抗体,为相关疾病治疗奠定基础。方法:在HEK293细胞中真核分泌表达人P-选择蛋白功能性片段,以此蛋白片段作为抗原,利用本室构建的大容量全合成人源性噬菌体抗体库进行筛选,经过3轮固相筛选后,阳性克隆得到富集;将其中富集效果最好的一株单链抗体A1改造成全抗体(IgG1),重组质粒转染H293细胞后,抗体得到表达;表达后在全抗体水平上用ELISA和Western印迹分别验证了A1抗体的特异性,并通过非竞争ELISA方法初步测定这株抗体的亲和力。结果:3轮筛选得到3株特异性噬菌体抗体,其中富集效果最好的单链抗体A1改造成全抗体形式后特异性良好,抗体亲和力Kd=2×10-8 mol/L。结论:筛选得到一株特异性较好的抗P-选择蛋白人源性单克隆抗体A1,其特异性和亲和力较好,有继续开发的价值。     

人源抗EPO基因工程抗体重链可变区的克隆和鉴定

利用噬菌体抗体显示技术筛选 EPO的人源抗体 ,得到了抗 EPO的人源抗体的重链基因。此抗体基因在噬菌体表面呈现的抗体分子具有良好的抗体活性和特异性。为制备完整的、具有更高亲和力的抗体打下了基础。     

亲和层析法用于噬菌体抗体库的筛选

本研究报道一种基于固定化金属亲和层析(IMAC)的噬菌体抗体库液相筛选方法。将纯化的带有His标签的抗原与噬菌体抗体库混合,噬菌体抗体与抗原充分结合后再加入亲和介质,使噬菌体抗体抗原复合物通过His标签与介质结合,然后通过充分洗涤去除非特异性噬菌体抗体,最后将特异性噬菌体抗体洗脱下来,感染TG1,进行下一轮筛选。整个筛选过程中抗原与抗体的结合在液相中完成,不仅消除了固相介质对抗原表位的影响,也更有利于噬菌体抗体与抗原的充分作用。将此方法应用于HEV NE2蛋白特异性人源噬菌体抗体的筛选,抗原竞争ELISA,阳性血清阻断,可溶性单链抗体表达检测及测序结果表明,最终获得2个特异性人源抗体。     

鼠源性抗雄性特异性抗原噬菌体Fab抗体的制备及分析

利用噬菌体抗体库筛选技术获得抗雄性特异性抗原的噬菌体Fab抗体,首次采用雄鼠脾细胞对鼠源性抗雄性特异性抗原噬菌体Fab抗体库进行3轮亲和富集和2轮雌鼠脾细胞吸附,对筛选后特异性噬菌体Fab抗体进行ELISA分析,重组率鉴定及基因测序分析。结果显示,5次筛选后的15个菌落中有9个能产生抗雄性特异性抗原特异性噬菌体抗体,噬菌体Fab抗体的基因重组率为60%,E5克隆的重链、轻链可变区序列分别属于VH1和VκⅣ基因家族,这为挑选出高亲和力的抗雄性特异性抗原噬菌体Fab抗体奠定了实验基础,将推进雄性特异性抗原及其抗体的研究进程,并为性别控制研究开创新途径。     

Aptamers as affinity reagents for clinical proteomics

Application of proteomic results to scientific and medical practice will depend in many respects on progress of affinity microchips technologies. This determines continuous search for inexpensive and robust affinity reagents alternative to monoclonal antibodies. Among synthetic mimetics of antibodies, the oligonucleotide aptamers are of the greatest interest as the affinity reagents due to the possibility to automate their selection and due to the low cost of oligonucleotide synthesis. In the review we consider the problems related to the automation and optimization of aptamer selection and also to selection of photoaptamers capable to form photoinduced covalent complexes with the protein targets. The existing approaches to the post-selection modification of the aptamers to increase their affinity and selectivity to protein targets are discussed.     

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

The demand for antibodies that fulfill the needs of both basic and clinical research applications is high and will dramatically increase in the future. However, it is apparent that traditional monoclonal technologies are not alone up to this task. This has led to the development of alternate methods to satisfy the demand for high quality and renewable affinity reagents to all accessible elements of the proteome. Toward this end, high throughput methods for conducting selections from phage-displayed synthetic antibody libraries have been devised for applications involving diverse antigens and optimized for rapid throughput and success. Herein, a protocol is described in detail that illustrates with video demonstration the parallel selection of Fab-phage clones from high diversity libraries against hundreds of targets using either a manual 96 channel liquid handler or automated robotics system. Using this protocol, a single user can generate hundreds of antigens, select antibodies to them in parallel and validate antibody binding within 6-8 weeks. Highlighted are: i) a viable antigen format, ii) pre-selection antigen characterization, iii) critical steps that influence the selection of specific and high affinity clones, and iv) ways of monitoring selection effectiveness and early stage antibody clone characterization. With this approach, we have obtained synthetic antibody fragments (Fabs) to many target classes including single-pass membrane receptors, secreted protein hormones, and multi-domain intracellular proteins. These fragments are readily converted to full-length antibodies and have been validated to exhibit high affinity and specificity. Further, they have been demonstrated to be functional in a variety of standard immunoassays including Western blotting, ELISA, cellular immunofluorescence, immunoprecipitation and related assays. This methodology will accelerate antibody discovery and ultimately bring us closer to realizing the goal of generating renewable, high quality antibodies to the proteome.     

An epitope-directed antibody affinity maturation system utilizing mammalian cell survival as readout

Upon developing therapeutically potent antibodies, there are significant requirements, such as increasing their affinity, regulating their epitope, and using native target antigens. Many antibody selection systems, such as a phage display method, have been developed, but it is still difficult to fulfill these requirements at the same time. Here, we propose a novel epitope-directed antibody affinity maturation system utilizing mammalian cell survival as readout. This system is based on the competition of antibody binding, and can target membrane proteins expressed in a native form on a mammalian cell surface. Using this system, we successfully selected an affinity-matured anti-ErbB2 single-chain variable fragment variant, which had the same epitope as the original one. In addition, the affinity was increased mainly due to the decrease in the dissociation rate. This novel cell-based antibody affinity maturation system could contribute to directly obtaining therapeutically potent antibodies that are functional on the cell surface.     

Antibody engineering for the analysis of affinity maturation of an anti-hapten response.

The influence of structural variation, previously observed in a panel of V186.2 VH/V lambda 1-expressing anti-NP antibodies from the secondary response, on the affinity of these antibodies was examined by site-specific mutagenesis and recombinant antibody construction. A tryptophan----leucine exchange at position 33 in the VH segment of all but one of the high-affinity antibodies is the most frequently observed somatic mutation and by itself leads to a 10-fold higher affinity; all other somatic exchanges are irrelevant for affinity selection. In the single case of a high-affinity antibody without this common exchange, high affinity is mediated by a combination of mutations (including a one-codon deletion) in VH and the particular D-JH rearrangement carried by this antibody. The data indicate that the pattern of somatic diversification through hypermutation is shaped by affinity selection, but that only a single point mutation is available in the VH and the VL gene of lambda 1 chain-bearing anti-NP antibodies which by itself leads to an increase of hapten-binding affinity. Based on the analysis of two secondary response antibodies from which somatic mutations in VH and VL have been eliminated, it is also concluded that the recruitment of B cell clones into the pathway of hypermutation involves a mechanism which is not based upon affinity differences towards the antigen.     

Emerging trends in the synthesis and improvement of hapten-specific recombinant antibodies

A key requirement for successful immunotherapeutic and immunodiagnostic applications is the availability of antibodies with high affinity and specificity. In the past, polyclonal antibodies from hyperimmunized animals or monoclonal antibodies from hybridoma cell lines were used extensively and profitably in medicine and immunotechnology. Antibody-based diagnostics, such as immunoassays, are also widely accepted because of their high sensitivity and ease of use as compared to conventional chromatographic techniques. While immunoassays have been used to monitor organic chemical contaminants such as pesticides, food preservatives, antibiotics in agricultural and food industries, hapten-specific antibodies with the desired affinity and specificity are generally difficult to obtain. With the advent of recombinant DNA technology, antibody genes can be amplified and selected through phage display, cell surface display, or cell-free display systems. A particularly useful feature common to all these display systems is the linking of the phenotype and genotype of antibodies during selection. This allows easy co-selection of the desired antibodies and their encoding genes based on the binding characteristics of the displayed antibodies. The selected antibody DNA can be further manipulated for high-level expression, post-translation modification, and/or affinity and specificity improvement to suit their particular applications. Several hapten-specific antibodies, which were successfully selected and engineered to high specificity and affinity using display technologies, have been found to be amenable to conventional immunoassay development. In this review, we will examine different formats of immunoassays designed for hapten identification and various display technologies available for antibody selection and improvement.     

Novartis Medal Lecture. Antibodies: a paradigm for the evolution of molecular recognition

Novel proteins have been elaborated over evolutionary time by an iterative alternation of mutation and selection. In a similar way, the humoral immune system also uses an iterative alternation of mutation and selection to generate novel antibodies that display a high affinity for their cognate antigen -- but this is achieved in a matter of a days. Gene rearrangement is used to produce a primary repertoire of antibodies and, on entering the body, antigen triggers the clonal expansion of those B lymphocytes that express a cognate antibody, albeit one of low affinity. Rapid and specific affinity maturation is then achieved by subjecting the immunoglobulin genes in the rapidly expanding B cells to a period of intense mutation. The intensity of this mutational assault is tolerated because it is targeted specifically to the immunoglobulin genes, causing relatively little damage to other loci. Antigen-mediated selection then allows the preferential expansion of those mutants expressing antibodies displaying improved binding characteristics. Here, studies are described that have been performed to glean insight into the mechanisms of the hypermutation and selection processes. Experiments are also described in which an attempt has been made to recapitulate aspects of physiological antibody generation in vitro, allowing the development of novel approaches to the generation of proteins with high-affinity binding sites.     

Clustered H chain somatic mutations shared by anti-p-azophenylarsonate antibodies confer enhanced affinity and ablate the cross-reactive idiotype

A cluster of four consecutive CDR2 somatic mutations are shared by the VH regions of two independently isolated hybridoma antibodies with specificity for p-azophenylarsonate (Ars). The mutations appear to be derived by a series of independent events. To assess the influence of these shared somatic mutations on antibody affinity for Ars and on idiotypy, we introduced them, via site-directed mutagenesis, into the V region of an anti-Ars antibody that was otherwise unmutated and we eliminated them from the mutated context of one of the two antibodies in which they were originally found. Results of affinity measurements by fluorescence quenching and of idiotypic binding assays performed on these engineered mutants demonstrated that the shared mutations increased affinity for Ars and eliminated the predominant Id associated with strain A anti-Ars antibodies and four of five idiotypes defined by anti-idiotypic mAb. These results support the interpretation that a strong affinity-based selection pressure has favored the clonal expansion of B cells with receptors containing these mutations despite the loss of a predominant Id. Thus, in producing antibodies containing V regions conferring high affinity for Ag, the combined processes of somatic mutation and clonal selection have generated a common structural solution through parallel repeats.     

Peptide epitope identification by affinity selection on bacteriophage MS2 virus-like particles

Filamentous phages are now the most widely used vehicles for phage display and provide efficient means for epitope identification. However, the peptides they display are not very immunogenic because they normally fail to present foreign epitopes at the very high densities required for efficient B-cell activation. Meanwhile, systems based on virus-like particles (VLPs) permit the engineered high-density display of specific epitopes but are incapable of peptide library display and affinity selection. We developed a new peptide display platform based on VLPs of the RNA bacteriophage MS2. It combines the high immunogenicity of MS2 VLPs with the affinity selection capabilities of other phage display systems. Here, we describe plasmid vectors that facilitate the construction of high-complexity random sequence peptide libraries on MS2 VLPs and that allow control of the stringency of affinity selection through the manipulation of display valency. We used the system to identify epitopes for several previously characterized monoclonal antibody targets and showed that the VLPs thus obtained elicit antibodies in mice whose activities mimic those of the selecting antibodies.     

Therapeutic antibodies: Discovery and development using the ProteOn XPR36 biosensor interaction array system

Therapeutic monoclonal antibodies are becoming a significant and rapidly growing class of therapeutic pharmaceuticals. Their discovery and development requires fast and high-throughput methodologies for screening and selecting appropriate candidate antibodies having high affinity for the target as well as high specificity and low cross-reactivity. This study demonstrates the use of the ProteOn XPR36 protein interaction array system and its novel approach, termed One-Shot Kinetics, for the rapid screening and selection of high-affinity antibodies. This approach allows multiple quantitative protein binding analyses in parallel, providing association, dissociation, and affinity constants for several antibodies or supernatants simultaneously in one experiment. We show that the ProteOn XPR36 system is a valuable tool for use across multiple stages of the therapeutic antibody discovery and development process, enabling efficient and rapid screening after panning, affinity maturation, assay validation, and clone selection.